104.79
-1.99(-1.86%)
Currency In USD
| Previous Close | 106.78 |
| Open | 106.64 |
| Day High | 107.08 |
| Day Low | 103 |
| 52-Week High | 120.32 |
| 52-Week Low | 7.58 |
| Volume | 318,349 |
| Average Volume | 824,480 |
| Market Cap | 4.85B |
| PE | -28.87 |
| EPS | -3.63 |
| Moving Average 50 Days | 105.42 |
| Moving Average 200 Days | 57.67 |
| Change | -1.99 |
If you invested $1000 in Celcuity Inc. (CELC) since IPO date, it would be worth $7,333.1 as of February 21, 2026 at a share price of $104.79. Whereas If you bought $1000 worth of Celcuity Inc. (CELC) shares 5 years ago, it would be worth $6,312.65 as of February 21, 2026 at a share price of $104.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Celcuity Appoints Charles Romp to its Board of Directors
GlobeNewswire Inc.
Feb 12, 2026 9:05 PM GMT
MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of D
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 12:05 PM GMT
MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Guggenheim Emerging Outlook: Biote
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
GlobeNewswire Inc.
Jan 20, 2026 12:30 PM GMT
FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, t